CELEBREX 200MG CAPSULE contains Celecoxib which belongs to group of medicines called Non-steroidal anti-inflammatory drugs. CELEBREX 200MG CAPSULE is used in adults to manage osteoarthritis (degenerative joint disease), rheumatoid arthritis (inflammatory disease of joints), ankylosing spondylitis (chronic back pain), acute pain and primary dysmenorrhea (menstrual cramps).
CELEBREX 200MG CAPSULE is also used to manage juvenile rheumatoid arthritis (in children aged 2 years and above).
CELEBREX 200MG CAPSULE is not recommended for use in patients allergic to Celecoxib, sulfonamides, aspirin and/or other NSAIDs. It is also not recommended for use in patients with/had a history of an ulcer in stomach/intestines, bleeding in stomach/intestines, blood circulation problems (such as peripheral arterial disease), red itchy welts, inflammatory disease of the intestines (such as ulcerative colitis/Crohn’s disease).
The medicine is also not indicted for use in patients suffering from lung problems (such as asthma), heart diseases (such as heart failure, recent heart attack, heart block), severe liver disease (such as advanced hepatic insufficiency) and/or kidney disease (such as advanced renal insufficiency).
Before taking CELEBREX 200MG CAPSULE, inform your doctor if you have diabetes, raised blood pressure, increased cholesterol, signs of fluid retention (such as swollen ankles and feet) and/or hyperkalemia (increased potassium level in blood).
CELEBREX 200MG CAPSULE is not recommended for use in pregnant and breast-feeding women.
CELEBREX 200MG CAPSULE should be used with caution in children and adolescents (aged 2 to 17 years) to manage only juvenile rheumatoid arthritis and is advised to be used with caution in elderly patients (aged 65 years/above) after consulting the doctor.
The most common side effects of taking CELEBREX 200MG CAPSULE are high blood pressure, shortness of breath, sore throat, cough, headache, nausea and dizziness. Consult your doctor if any of these symptoms worsen.
How can CELEBREX 200MG CAPSULE be used::Take CELEBREX 200MG CAPSULE as advised by your doctor to avoid serious side effects. Do not change the dose or stop taking CELEBREX 200MG CAPSULE at the same time as taking different NSAID or different calcium-fortified products such as tablets, capsules, oral suspension, syrup, patches, pastes,ainmentdepending on the form of CELEBREX 200MG CAPSULE you are taking. Your doctor may change the dose of CELEBREX 200MG CAPSULE depending on your response.
You may feel drowsy, dizzy, tired or not being alert. Avoid consuming alcohol with CELEBREX 200MG CAPSULE, as it may make you more sensitive to the sun. You and your doctor should discuss the risks and benefits of taking CELEBREX 200MG CAPSULE (and other NSAIDs) in advance before using it together with other NSAID or CELEBREX 200MG CAPSULE therapies like aspirin or ibuprofen.
Inform your doctor if you have specifically prescribed CELEBREX 200MG CAPSULE for you. Some Osteoarthritis Drugs studies suggest that taking CELEBREX 200MG CAPSULE may be associated with an increased risk of cardiovascular diseases. studies in animals and humans found that people taking CELEBREX 200MG CAPSULE experienced a 10- to 20-fold increase in heart attack risk over non-users. Studies in patients show that taking CELEBREX 200MG CAPSULE may be associated with an increased risk of cardiovascular diseases, dose-dependent in mechanism.
possible side effects:
headache, indigestion, muscle pain, back pain, muscle aches, rash, flushing, upper back pain, upper respiratory infection, diarrhea, blurred vision, code-weening, muscle pain, fever, joint pain, headache, soreness, itching, anorexia, weight loss, nausea and diarrhea. All these side effects are generally mild and do not require medical attention].
Celebrex, also known as celecoxib, is a non-steroidal anti-inflammatory drug (NSAID) used to relieve various inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It works by inhibiting the production of prostaglandins, which are responsible for inflammation, pain, and pain signals in the body. Here we will provide an overview of Celebrex, its mechanism of action, adverse effects, and more.
The global Celebrex market has been experiencing significant growth. As of 2023, the market size was valued at approximately USD 1.2 billion and is expected to grow at a CAGR of 3.9% from 2024 to 2030[1].
North America, particularly the United States, is Ase-related. The growth rate of US-specific Celebrex market from 2024 to 2030 is! The US Celebrex market is valued at approximately USD 3.11 billion in 2024 and is expected to grow at a CAGR of 3.2% from 2024 to 2030[5].
The Asia Pacific region, particularly India, is Ase-related. The Celebrex market was valued at approximately USD 2.96 billion in 2024 and is expected to grow at a CAGR of 2.0% from 2024 to 2030[4].
Oeaturing in the global Celebrex market, Asia Pacific is Ase-related. The Celebrex market was valued at approximately USD 1.9 billion in 2024 and is expected to grow at a CAGR of 3.2% from 2024 to 2030[5].
Latin America and Middle East & Africa are B2B players. The Latin America market was valued at approximately USD 1.2 billion in 2024 and is expected to grow at a CAGR of 2.2% from 2024 to 2030[2].
Several factors are driving the growth of the Celebrex market:
The development of next-day & offline medical P200 vaccination technology has made Celebrex a accessible option for the Primary Healthcare population. This vaccination technology is a crucial factor for reducing the risk of severe gastrointestinal bleeding and related complications[3][4].
The cost of Celebrex has been steadily rising due to several factors:
The development of P3 epylesterase inhibitors in the last 20 years, such as gabapentin (Omoustianche), have seen significant advancements in delivery technology. This is due to the fact that the drug is taken once daily and does not have to be repeated every day[3].
The development of drug delivery systems has been increasing the drug efficacy and reducing the risk of adverse reactions, such as bone marrow suppression and osteoporosis,[1].
The cost-effectiveness of Celebrex in terms of cardiovascular events and gastrointestinal adverse reactions is significant[1].
One of the main costs-effectivenessi- related factors is the cost-benefit analysis of Celebrex based on various reviews. A study on cardiovascular events showed that the cost-effectiveness of Celebrex has been extensively studied through the review of patient-specific patient-specific reviews and multiple payment plans, as well as through various payment options such as deductibles and rebates[3].
Celebrex is well-tolerated. However, like any medication, it can have side effects, such as gastrointestinal bleeding, hot flashes, and menstrual irregularities,[1].
WARNING:
WARNING
Do not use:
This is not a complete list of side effects. If you notice any side effects not listed above, contact your doctor or pharmacist.
PREGNANCY:You should not use certain pregnancy and/or breast-feeding products if you are pregnant, if you are planning to become pregnant, or if you are breast-feeding. See your doctor for a list of medications and conditions that may interact with Celebrex. See also How Do I Know When to Avoid Using an Antidepressant?
Lactation:Do not use Celebrex if you are breastfeeding. Do not breastfeed while taking Celebrex. You should not breastfeed while taking Celebrex if you are already pregnant. If you are planning to breastfeed, discuss with your doctor how much time you will have to prepare your diet and what other measures you should take while you are using Celebrex.
Talk to your doctor or pharmacist before taking Celebrex if you are currently taking any of the following medications:
· Nitrates used to treat angina and chest pain (angina pectoris)
· Stimulators such as guanylate cyclase stimulators such as adalimumab (“Adempas”) and etabimate (“Eletation”) medicines
· Nonsteroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen (Advil, Motrin), naproxen (Aleve), and celecoxib (Adcirca)
· Medications that relax blood vessels such as prostaglandins and prostacyclins
· Alpha blockers such as atenolol (Tenormin) and nebivolol (Nebivol)
· Alpha-blockers such as atenolol (Tenormin) and atenolol (Tenormin) and nebivolol (Nebivol)
· Other medicines such as diuretics, and medicines to treat high blood pressure or high blood pressure that may interact with Celebrex.
NEW YORK (CNN) -- Pfizer Inc. is seeking a new $10 billion bid from Pfizer and other pharmaceutical companies to develop an arthritis drug with a less expensive and safer side effect, Pfizer said Thursday.
The bid includes an experimental anti-inflammatory drug called Bextra that Pfizer plans to offer a month ago.
The drug is the first approved by the U. S. Food and Drug Administration for the treatment of osteoarthritis in patients in the United States and Europe.
Pfizer and its U. and European distributors are seeking $10 billion, according to Pfizer's annual report on pharmaceuticals and sales.
The company said its $10 billion-a-year bid has resulted in a substantial increase in the number of new drugs submitted, including two new drugs from Johnson & Johnson that will cost between $2 billion and $5 billion each.
Pfizer said it will continue to receive final approval from the FDA for Bextra from Nov. 30 through Feb. 11.
"We've seen this type of drug in the past, but it's important to remember that it is not a drug that will be given to patients or the general public," said Richard M. Weisberg, Pfizer's vice president of worldwide sales. "It is a drug that should be considered for the treatment of osteoarthritis."
The drug is used to treat arthritis.
It's also used as an anti-inflammatory for arthritis. It is also used to reduce inflammation and pain associated with arthritis, such as arthritis of the shoulder, arms and spine.
Pfizer's sales of Bextra and the other new drugs it has submitted to the FDA are on a constant growth basis.
The company said it has no plans to introduce Bextra again until at least May. "We are in a good position to continue the clinical trials of Bextra for osteoarthritis," Pfizer said in a statement.
The company also said it will continue to receive final approval from the FDA for the next two years for other similar drugs in the same class of painkillers. For example, the company has received final approval for Celebrex from the FDA.
Pfizer said it expects to receive final approval for pain management and joint pain treatments in the fourth quarter and for arthritis drugs in the next six months. It also expects to receive final approval for arthritis drug Celebrex from the FDA for the third quarter of this year.
Pfizer said it has no plans to introduce Bextra again until at least May.
Read MoreEarlier this week, Pfizer's chief executive officer, John V. Lechleiter, said the company has received final approval from the FDA for Bextra from Nov.
Pfizer spokeswoman Nancy Kavoussi said, "The company is disappointed with Pfizer's decision to pursue a Phase III clinical trial for Bextra and Celebrex. We are disappointed with the FDA's decision to suspend development of Bextra, Celebrex and other pain medications in Europe and Canada, and we believe that the companies will continue to follow their lead in advancing Bextra and Celebrex."
The company's chief executive officer, John V. Lechleiter, said Pfizer's decision to pursue a Phase III trial for Bextra and Celebrex is a good one.
The company's decision to pursue a Phase III clinical trial for Bextra and Celebrex is a good one. Pfizer's shares closed at $43.53 on Wednesday afternoon after shares of the company's stock fell 21 cents to $23.86.
The Pfizer Company reported a loss of $13.2 billion, or $5.56 per share, or $1.73 per share, on Monday. That's up from $8.55 billion, or $2.75 per share, on Wednesday.
Pfizer Inc., the world's largest pharmaceutical company, said it has reached an agreement with the company to resolve its dispute with Pfizer.
The company said in a statement: "This is the first time a major pharmaceutical company has agreed to pay for the costs and burdens of litigation and for legal and regulatory activities that impact its business, including litigation involving the pharmaceutical industry. We continue to believe that the settlement with Pfizer is fair and fair. Pfizer has no intention of continuing to engage in litigation, including in this case, and will continue to vigorously defend itself against any claims that it may have made to our regulatory agency.
Stade de France Pharmacy